Latest Breaking News On - Napp pharmaceutical research - Page 1 : vimarsana.com

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-

Simon cooperChris erdmanPraveen tipirneniKey additions to morphic leadership teamDevelopment programNapp pharmaceutical researchExchange commissionUniversity of newcastle upon tyne medical schoolMorphic holding incWyeth researchHuman genome sciencesKadmon holdingsSecurities exchangeChief medicalChief medical officerRecent corporate

Keros Therapeutics Appoints Si - GuruFocus com

Keros Therapeutics Appoints Si - GuruFocus com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.

Newcastle upon tyneUnited kingdomMike biegaJasbirs seehraSimon cooperClaudia ordonezMediumme ltdWyeth researchKeros therapeutics incUniversity of newcastle upon tyneGlobal programClinical research at human genome sciencesAsset strategy leader at abbvie incKadmon holdings incNapp pharmaceutical researchNovartis international

Keros Therapeutics Appoints Simon Cooper, M B B S as Chief Medical Officer

Keros Therapeutics Appoints Simon Cooper, M B B S as Chief Medical Officer
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.